A review published in Neurotherapeutics explores cannabidiol (CBD), a non-psychoactive component of Cannabis sativa, as a potential treatment for anxiety disorders. The authors analyzed preclinical and clinical studies, finding that acute CBD administration shows promise in reducing symptoms of generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. However, they note a lack of research on the effects of chronic CBD use and its efficacy in clinical populations. The review concludes that while CBD has considerable potential as an anxiety treatment, further studies are needed to understand its long-term effects and therapeutic applications.